Analysts Offer Predictions for CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Caribou Biosciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings per share of ($2.17) for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $1.18 on Wednesday. The firm has a market capitalization of $109.75 million, a price-to-earnings ratio of -0.72 and a beta of 2.44. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.00. The business has a fifty day moving average price of $0.92 and a 200-day moving average price of $1.28.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $1.48 million.

Institutional Investors Weigh In On Caribou Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP increased its holdings in Caribou Biosciences by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company’s stock valued at $1,779,000 after acquiring an additional 214,239 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Caribou Biosciences in the 4th quarter worth about $649,000. Nuveen Asset Management LLC increased its holdings in shares of Caribou Biosciences by 23.6% in the 4th quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company’s stock worth $526,000 after buying an additional 63,096 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock worth $3,969,000 after buying an additional 2,062,563 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Caribou Biosciences by 12.0% in the 4th quarter. Barclays PLC now owns 145,417 shares of the company’s stock worth $231,000 after buying an additional 15,578 shares during the last quarter. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.